Tau PET imaging with ¹⁸F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study.

ABSTRACT: ¹⁸F-PI-2620 is a PET tracer with high binding affinity for aggregated tau, a key pathologic feature of Alzheimer disease (AD) and other neurodegenerative disorders. Preclinically, ¹⁸F-PI-2620 binds to both 3-repeat and 4-repeat tau isoforms. The purpose of this first-in-humans study was to evaluate the ability of ¹⁸F-PI-2620 to detect tau pathology in AD patients using PET imaging, as well as to assess the safety and tolerability of this new tau PET tracer. Methods: Participants with a clinical diagnosis of probable AD and healthy controls (HCs) underwent dynamic ¹⁸F-PI-2620 PET imaging for 180 min. ¹⁸F-PI-2620 binding was assessed visually and quantitatively using distribution volume ratios (DVR) estimated from noninvasive trac

SUBMITTER: Mueller A 

PROVIDER: S-EPMC7262222 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature